Evidence map›Paper›PMID 27539610›Full record

SynthesisNeurosurgical review2018

A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury.

Iman El Sayed, Adel Zaki, Akram M Fayed, Gihan M Shehata, Sherif Abdelmonem

Registry-linked trialAbstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in Neurosurgical review, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06052787 (The Impact and Outcomes of Combined Cerebrolysin and Amantadine Sulfate Administration on Management of Patients With Traumatic Brain Injury in the ICU), which is not on this map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06052787 phase3completednot on this mapstarted 2023, after this paper: background citation

The Impact and Outcomes of Combined Cerebrolysin and Amantadine Sulfate Administration on Management of Patients With Traumatic Brain Injury in the ICU

TypeinterventionalSponsorAin Shams UniversityRan2023 to 2025Enrolled150ConditionsTraumatic Brain InjuryArmsCerebrolysin, amantadine sulfate
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Pooled it
  3. Cerebrolysin for vascular dementia.The Cochrane database of systematic reviews · 2019
    Pooled it
  4. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Preventive effects of seat belts on traumatic brain injury in motor vehicle collisions classified by crash severities and collision directions.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2021
    Article
  13. Role of Citicoline in the Management of Traumatic Brain Injury.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  14. Article
  15. Article
  16. Article
  17. [Expert consensus on neurorestorotherapy for infants/toddlers with brain injury].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2018
    Article
  18. Preventive Effects of Safety Helmets on Traumatic Brain Injury after Work-Related Falls.International journal of environmental research and public health · 2016
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Iman El SayedBiomedical Informatics and Medical Statistics Department, Medical Research Institute, Alexandria University, 165th Al Hureya Avenue, Alexandria, 21561, Egypt. emmystatistics@gmail.com.
Adel ZakiBiomedical Informatics and Medical Statistics Department, Medical Research Institute, Alexandria University, 165th Al Hureya Avenue, Alexandria, 21561, Egypt.
Akram M FayedCritical Care Medicine Department, Faculty of Medicine, Alexandria University, Sultan Hussein Street, Alexandria, Egypt.
Gihan M ShehataBiomedical Informatics and Medical Statistics Department, Medical Research Institute, Alexandria University, 165th Al Hureya Avenue, Alexandria, 21561, Egypt.
Sherif AbdelmonemCritical Care Medicine Department, Faculty of Medicine, Alexandria University, Sultan Hussein Street, Alexandria, Egypt.
Alexandria University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traumatic brain injury is a major problem worldwide. Our objective is to synthesize available evidence in the literature concerning the effectiveness of neuroprotective drugs (cerebrolysin, citicoline, and piracetam) on Glasgow outcome score (GOS), cognitive performance, and survival in traumatic brain injury patients. Comprehensive search of electronic databases, search engines, and conferences proceedings; hand search journals; searching reference lists of relevant articles, theses, and local publications; and contact of authors for incomplete data were performed. Studies included patients in all age groups regardless of severity of trauma. There was no publication date restriction. Two reviewers independently extracted data from each study. Fixed effect or random effects model selection depends on results of statistical tests for heterogeneity. The literature search yielded 13 studies. Patients treated with cerebrolysin (n = 112) had favorable GOS three times more than controls (OR 3.019; 95 % CI 1.76 to 5.16; p = 0.003*). The odds of cognition improvement in the treatment group was 3.4 times more than controls (OR 3.4; 95 % CI 1.82 to 5.21; p < 0.001*). Survival of cerebrolysin-treated patients did not differ from controls (103 patients; OR = 2.81; 95 % CI 0.905 to 8.76). Citicoline did not improve GOS (1355 patients; OR 0.96; 95 % CI 0.830 to 1.129; p = 0.676), cognitive performance (4 studies; 1291 patients; OR 1.35; 95 % CI 0.58 to 3.16; p = 0.478), and survival (1037 patients; OR = 1.38; 95 % CI 0.855 to 2.239). One study showed a positive effect of piracetam on cognition. Further research with high validity is needed to reach a solid conclusion about the use of neuroprotective drugs in cases of brain injury.

Indexed as

AdultAmino AcidsBrain Injuries, TraumaticCognition DisordersCytidine Diphosphate CholineGlasgow Outcome ScaleHumansNeuroprotective AgentsPiracetamTreatment OutcomeAmino AcidscerebrolysinCytidine Diphosphate CholineNeuroprotective AgentsPiracetamBrain injuriesCerebrolysinCerebrovascular traumaCytidine diphosphate cholinePiracetamTherapy

Identifiers

PMID27539610
OpenAlexW2511666301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.